Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.15252/emmm.201708203 http://scihub22266oqcxt.onion/10.15252/emmm.201708203 C5582408!5582408!28743783     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       EMBO+Mol+Med 2017 ; 9 (9): 1179-82 Nephropedia Template TP {{tp|p=28743783|t=2017. Rethinking the nonprofit foundation: an emerging niche in the rare disease ecosystem |pdf=|usr=}}{{28743783}} gab.com Text Rethinking the nonprofit foundation: an emerging niche in the rare disease ecosystem JO: EMBO Mol Med http://www.kidney.de/pget.php?&tw=1&pmid=28743783 #FOAvip In recent years, medical foundations have become increasingly influential, and now play an instrumental and integral role in the research and development of their disease area of interest. While some foundations have directly invested in taking drug candidates to the clinic, others have focused on creating specific tools for accelerating the identification and development of effective treatments. Here, we describe a new model, developed by the Children's Tumor Foundation (CTF), by which foundations may play a role in the rare disease ecosystem. On the one hand, the CTF uses its position to build bridges between academic scientists, biotech and pharmaceutical companies, and patients, to accelerate the development of treatments that really matter most to patients. On the other hand, it acts as a niche investor to fund an integrated platform for critical R&D endeavors?including elements such as a patient registry, biobank, and open data platforms?which smoothen the transition from basic discovery to clinical benefit. Currently, the Children's Tumor Foundation is launching a call to top finance experts to collaborate on building an innovative model that will guarantee long?term sustainability of this integrated platform (Fig 1). Twit Text FOAVip Rethinking the nonprofit foundation: an emerging niche in the rare disease ecosystem ????EMBO Mol Med http://www.kidney.de/pget.php?&tw=1&pmid=28743783 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28743783 #FOAvip English Wikipedia <ref>{{Cite pmid|28743783}}</ref> Rethinking the nonprofit foundation: an emerging niche in the rare disease ecosystem #MMPMID28743783 Bakker AC; La Rosa S EMBO Mol Med 2017[Sep]; 9 (9): 1179-82 PMID28743783show ga In recent years, medical foundations have become increasingly influential, and now play an instrumental and integral role in the research and development of their disease area of interest. While some foundations have directly invested in taking drug candidates to the clinic, others have focused on creating specific tools for accelerating the identification and development of effective treatments. Here, we describe a new model, developed by the Children's Tumor Foundation (CTF), by which foundations may play a role in the rare disease ecosystem. On the one hand, the CTF uses its position to build bridges between academic scientists, biotech and pharmaceutical companies, and patients, to accelerate the development of treatments that really matter most to patients. On the other hand, it acts as a niche investor to fund an integrated platform for critical R&D endeavors?including elements such as a patient registry, biobank, and open data platforms?which smoothen the transition from basic discovery to clinical benefit. Currently, the Children's Tumor Foundation is launching a call to top finance experts to collaborate on building an innovative model that will guarantee long?term sustainability of this integrated platform (Fig 1). äRethinking the nonprofit foundation: an emerging niche in the rare dis(epmc).pdf DeepDyve Pubget Overpricing